{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T08:49:17Z","timestamp":1772354957263,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["NIH 1R21NS095271-01A1"],"award-info":[{"award-number":["NIH 1R21NS095271-01A1"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006955","name":"Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["NIH 1R21NS095271-01A1"],"award-info":[{"award-number":["NIH 1R21NS095271-01A1"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl. Stroke Res."],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12975-023-01193-x","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:02:34Z","timestamp":1694620954000},"page":"1035-1049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of Stroke at a Delayed Timepoint with a Repurposed Drug Targeting Sigma 1 Receptors"],"prefix":"10.1007","volume":"15","author":[{"given":"Derek A.","family":"Schreihofer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhwanil","family":"Dalwadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seongcheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Oppong-Gyebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paromita","family":"Das-Earl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Schetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"1193_CR1","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1016\/j.biopha.2018.11.041","volume":"109","author":"L Goenka","year":"2019","unstructured":"Goenka L, Uppugunduri CR, Satyanarayana SKS, George M. Neuroprotective agents in Acute Ischemic Stroke-A Reality Check. Biomed Pharmacother. 2019;109:2539\u201347.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"1193_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ame2.12166","volume":"4","author":"SK Narayan","year":"2021","unstructured":"Narayan SK, et al. Preclinical animal studies in ischemic stroke: Challenges and some solutions. Animal Model Exp Med. 2021;4(2):104\u201315.","journal-title":"Animal Model Exp Med"},{"issue":"4","key":"1193_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/jcpt.13392","volume":"46","author":"C Chen","year":"2021","unstructured":"Chen C, et al. Clinical effects and safety of edaravone in treatment of acute ischaemic stroke: A meta-analysis of randomized controlled trials. J Clin Pharm Ther. 2021;46(4):907\u201317.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1193_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1474-4422(10)70314-8","volume":"10","author":"F Chollet","year":"2011","unstructured":"Chollet F, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123\u201330.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1193_CR5","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s00415-018-8935-3","volume":"265","author":"K Malhotra","year":"2018","unstructured":"Malhotra K, et al. Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials. J Neurol. 2018;265(8):1871\u20139.","journal-title":"J Neurol"},{"issue":"10","key":"1193_CR6","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1161\/STROKEAHA.121.034705","volume":"52","author":"E Lundstrom","year":"2021","unstructured":"Lundstrom E, et al. Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial. Stroke. 2021;52(10):3082\u20137.","journal-title":"Stroke"},{"key":"1193_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jocn.2021.01.005","volume":"86","author":"BA Strickland","year":"2021","unstructured":"Strickland BA, et al. Neuroprotective effect of minocycline against acute brain injury in clinical practice: A systematic review. J Clin Neurosci. 2021;86:50\u20137.","journal-title":"J Clin Neurosci"},{"key":"1193_CR8","doi-asserted-by":"crossref","unstructured":"Ghosh D et al. Drug repurposing for stroke intervention. Drug Discov Today. 2022.","DOI":"10.1016\/j.drudis.2022.03.003"},{"issue":"9","key":"1193_CR9","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1161\/STROKEAHA.121.032241","volume":"52","author":"PD Lyden","year":"2021","unstructured":"Lyden PD. Cerebroprotection for Acute Ischemic Stroke: Looking Ahead. Stroke. 2021;52(9):3033\u201344.","journal-title":"Stroke"},{"issue":"20 Suppl 2","key":"1193_CR10","first-page":"S178","volume":"97","author":"SM Desai","year":"2021","unstructured":"Desai SM, Jha RM, Linfante I. Collateral Circulation Augmentation and Neuroprotection as Adjuvant to Mechanical Thrombectomy in Acute Ischemic Stroke. Neurology. 2021;97(20 Suppl 2):S178\u201384.","journal-title":"Neurology"},{"issue":"9","key":"1193_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.tips.2019.07.006","volume":"40","author":"HR Schmidt","year":"2019","unstructured":"Schmidt HR, Kruse AC. The Molecular Function of sigma Receptors: Past, Present, and Future. Trends Pharmacol Sci. 2019;40(9):636\u201354.","journal-title":"Trends Pharmacol Sci"},{"key":"1193_CR12","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fnins.2019.00862","volume":"13","author":"DA Ryskamp","year":"2019","unstructured":"Ryskamp DA, et al. Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases. Front Neurosci. 2019;13:862.","journal-title":"Front Neurosci"},{"issue":"1","key":"1193_CR13","first-page":"97","volume":"16","author":"B Penke","year":"2018","unstructured":"Penke B, Fulop L, Szucs M, Frecska E. The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases. Curr Neuropharmacol. 2018;16(1):97\u2013116.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"1193_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3390\/biom12030363","volume":"12","author":"F Bogar","year":"2022","unstructured":"Bogar F, Fulop L, Penke B. Novel Therapeutic Target for Prevention of Neurodegenerative Diseases: Modulation of Neuroinflammation with Sig-1R Ligands. Biomolecules. 2022;12(3):363.","journal-title":"Biomolecules"},{"issue":"1","key":"1193_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0278-5846(96)00160-1","volume":"21","author":"T Maurice","year":"1997","unstructured":"Maurice T, Lockhart BP. Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry. 1997;21(1):69\u2013102.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"1193_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/jcbfm.2008.118","volume":"29","author":"Z Li","year":"2009","unstructured":"Li Z, et al. DHEA-neuroprotection and -neurotoxicity after transient cerebral ischemia in rats. J Cereb Blood Flow Metab. 2009;29(2):287\u201396.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"Pt 3","key":"1193_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/brain\/awq367","volume":"134","author":"K Ruscher","year":"2011","unstructured":"Ruscher K, et al. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain\u202f: a journal of neurology. 2011;134(Pt 3):732\u201346.","journal-title":"Brain : a journal of neurology"},{"key":"1193_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.nbd.2013.10.011","volume":"62","author":"C Katnik","year":"2014","unstructured":"Katnik C, et al. Treatment with afobazole at delayed time points following ischemic stroke improves long-term functional and histological outcomes. Neurobiol Dis. 2014;62:354\u201364.","journal-title":"Neurobiol Dis"},{"issue":"11","key":"1193_CR19","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1161\/STROKEAHA.114.005835","volume":"45","author":"R Urfer","year":"2014","unstructured":"Urfer R, et al. Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke. Stroke. 2014;45(11):3304\u201310.","journal-title":"Stroke"},{"key":"1193_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-3-319-50174-1_10","volume":"964","author":"L Nguyen","year":"2017","unstructured":"Nguyen L, et al. Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection. Adv Exp Med Biol. 2017;964:133\u201352.","journal-title":"Adv Exp Med Biol"},{"key":"1193_CR21","doi-asserted-by":"publisher","first-page":"136528","DOI":"10.1016\/j.neulet.2022.136528","volume":"774","author":"Y An","year":"2022","unstructured":"An Y, et al. Activation of the sigma-1 receptor attenuates blood-brain barrier disruption by inhibiting amyloid deposition in Alzheimer\u2019s disease mice. Neurosci Lett. 2022;774:136528.","journal-title":"Neurosci Lett"},{"issue":"10","key":"1193_CR22","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1007\/s11064-020-03092-1","volume":"45","author":"W Li","year":"2020","unstructured":"Li W, et al. Protective Mechanism and Treatment of Neurogenesis in Cerebral Ischemia. Neurochem Res. 2020;45(10):2258\u201377.","journal-title":"Neurochem Res"},{"key":"1193_CR23","doi-asserted-by":"publisher","first-page":"3889300","DOI":"10.1155\/2022\/3889300","volume":"2022","author":"SK Sims","year":"2022","unstructured":"Sims SK, et al. Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research. Neural Plast. 2022;2022:3889300.","journal-title":"Neural Plast"},{"issue":"1","key":"1193_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12863-018-0630-y","volume":"19","author":"J He","year":"2018","unstructured":"He J, et al. Molecular mechanism of estrogen-mediated neuroprotection in the relief of brain ischemic injury. BMC Genet. 2018;19(1):46.","journal-title":"BMC Genet"},{"issue":"6","key":"1193_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/1028415X.2017.1391933","volume":"22","author":"DA Schreihofer","year":"2019","unstructured":"Schreihofer DA, Oppong-Gyebi A. Genistein: mechanisms of action for a pleiotropic neuroprotective agent in stroke. Nutr Neurosci. 2019;22(6):375\u201391.","journal-title":"Nutr Neurosci"},{"key":"1193_CR26","doi-asserted-by":"publisher","first-page":"1732163","DOI":"10.1155\/2016\/1732163","volume":"2016","author":"N Shi","year":"2016","unstructured":"Shi N, Zhu C, Li L. Rehabilitation Training and Resveratrol Improve the Recovery of Neurological and Motor Function in Rats after Cerebral Ischemic Injury through the Sirt1 Signaling Pathway. Biomed Res Int. 2016;2016:1732163.","journal-title":"Biomed Res Int"},{"key":"1193_CR27","doi-asserted-by":"publisher","first-page":"832611","DOI":"10.3389\/fphar.2022.832611","volume":"13","author":"K Liu","year":"2022","unstructured":"Liu K, et al. Acute Administration of Metformin Protects Against Neuronal Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury via Regulation of the AMPK\/CREB\/BDNF Pathway. Front Pharmacol. 2022;13:832611.","journal-title":"Front Pharmacol"},{"key":"1193_CR28","doi-asserted-by":"publisher","first-page":"107129","DOI":"10.1016\/j.vascn.2021.107129","volume":"113","author":"DA Dalwadi","year":"2022","unstructured":"Dalwadi DA, et al. Brain-derived neurotrophic factor for high-throughput evaluation of selective Sigma-1 receptor ligands. J Pharmacol Toxicol Methods. 2022;113:107129.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"3","key":"1193_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bcmd.2009.12.004","volume":"44","author":"S Kim","year":"2010","unstructured":"Kim S, et al. Vivo-Morpholino knockdown of alphaIIb: A novel approach to inhibit thrombocyte function in adult zebrafish. Blood Cells Mol Dis. 2010;44(3):169\u201374.","journal-title":"Blood Cells Mol Dis"},{"key":"1193_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neuint.2017.02.003","volume":"105","author":"DA Dalwadi","year":"2017","unstructured":"Dalwadi DA, Kim S, Schetz JA. Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia. Neurochem Int. 2017;105:21\u201331.","journal-title":"Neurochem Int"},{"issue":"2","key":"1193_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/jnr.24981","volume":"100","author":"A Oppong-Gyebi","year":"2022","unstructured":"Oppong-Gyebi A, et al. Long-term hypogonadism diminishes the neuroprotective effects of dietary genistein in young adult ovariectomized rats after transient focal ischemia. J Neurosci Res. 2022;100(2):598\u2013619.","journal-title":"J Neurosci Res"},{"issue":"7 Pt 2","key":"1193_CR32","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1523\/JNEUROSCI.15-07-05372.1995","volume":"15","author":"CV Borlongan","year":"1995","unstructured":"Borlongan CV, Sanberg PR. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci. 1995;15(7 Pt 2):5372\u20138.","journal-title":"J Neurosci"},{"issue":"3","key":"1193_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1161\/01.STR.17.3.472","volume":"17","author":"JB Bederson","year":"1986","unstructured":"Bederson JB, et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17(3):472\u20136.","journal-title":"Stroke"},{"issue":"2","key":"1193_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/jcbfm.1990.47","volume":"10","author":"RA Swanson","year":"1990","unstructured":"Swanson RA, et al. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 1990;10(2):290\u20133.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"1193_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jneumeth.2008.10.009","volume":"177","author":"S Sauerzweig","year":"2009","unstructured":"Sauerzweig S, Baldauf K, Braun H, Reymann KG. Time-dependent segmentation of BrdU-signal leads to late detection problems in studies using BrdU as cell label or proliferation marker. J Neurosci Methods. 2009;177(1):149\u201359.","journal-title":"J Neurosci Methods"},{"issue":"2","key":"1193_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/156720206776875849","volume":"3","author":"CT Ajmo Jr","year":"2006","unstructured":"Ajmo CT Jr, et al. Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats. Curr Neurovasc Res. 2006;3(2):89\u201398.","journal-title":"Curr Neurovasc Res"},{"issue":"9","key":"1193_CR37","doi-asserted-by":"publisher","first-page":"e45118","DOI":"10.1371\/journal.pone.0045118","volume":"7","author":"K Ruscher","year":"2012","unstructured":"Ruscher K, et al. Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke. PLoS ONE. 2012;7(9):e45118.","journal-title":"PLoS ONE"},{"key":"1193_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2007.08.068","volume":"1181","author":"JA Schetz","year":"2007","unstructured":"Schetz JA, et al. A prototypical Sigma-1 receptor antagonist protects against brain ischemia. Brain Res. 2007;1181:1\u20139.","journal-title":"Brain Res"},{"issue":"10","key":"1193_CR39","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/WNR.0000000000000162","volume":"25","author":"S Sato","year":"2014","unstructured":"Sato S, Kawamata T, Kobayashi T, Okada Y. Antidepressant fluvoxamine reduces cerebral infarct volume and ameliorates sensorimotor dysfunction in experimental stroke. NeuroReport. 2014;25(10):731\u20136.","journal-title":"NeuroReport"},{"issue":"11","key":"1193_CR40","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1021\/acschemneuro.1c00032","volume":"12","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, et al. The Protective Effects of Dexmedetomidine against Hypoxia\/Reoxygenation-Induced Inflammatory Injury and Permeability in Brain Endothelial Cells Mediated by Sigma-1 Receptor. ACS Chem Neurosci. 2021;12(11):1940\u20137.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"1193_CR41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/j.1471-4159.2007.05058.x","volume":"104","author":"YC Shen","year":"2008","unstructured":"Shen YC, et al. Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. J Neurochem. 2008;104(2):558\u201372.","journal-title":"J Neurochem"},{"issue":"5","key":"1193_CR42","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/NRL.0b013e3180f60bd8","volume":"13","author":"LL Werling","year":"2007","unstructured":"Werling LL, Lauterbach EC, Calef U. Dextromethorphan as a potential neuroprotective agent with unique mechanisms of action. Neurologist. 2007;13(5):272\u201393.","journal-title":"Neurologist"},{"issue":"2","key":"1193_CR43","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0006-8993(99)01125-7","volume":"821","author":"YC Chou","year":"1999","unstructured":"Chou YC, et al. Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan. Brain Res. 1999;821(2):516\u20139.","journal-title":"Brain Res"},{"issue":"6","key":"1193_CR44","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1007\/s12035-017-0697-x","volume":"55","author":"P Sanchez-Blazquez","year":"2018","unstructured":"Sanchez-Blazquez P, Pozo-Rodrigalvarez A, Merlos M, Garzon J. The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9. Mol Neurobiol. 2018;55(6):4940\u201351.","journal-title":"Mol Neurobiol"},{"issue":"11","key":"1193_CR45","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1007\/s12035-021-02524-5","volume":"58","author":"NH Wu","year":"2021","unstructured":"Wu NH, et al. Emerging Benefits: Pathophysiological Functions and Target Drugs of the Sigma-1 Receptor in Neurodegenerative Diseases. Mol Neurobiol. 2021;58(11):5649\u201366.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1193_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neulet.2008.05.055","volume":"440","author":"K Kikuchi-Utsumi","year":"2008","unstructured":"Kikuchi-Utsumi K, Nakaki T. Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus. Neurosci Lett. 2008;440(1):19\u201322.","journal-title":"Neurosci Lett"},{"issue":"7","key":"1193_CR47","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/syn.21549","volume":"66","author":"M Fujimoto","year":"2012","unstructured":"Fujimoto M, et al. Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse. 2012;66(7):630\u20139.","journal-title":"Synapse"},{"key":"1193_CR48","doi-asserted-by":"publisher","first-page":"1969482","DOI":"10.1155\/2020\/1969482","volume":"2020","author":"W Liu","year":"2020","unstructured":"Liu W, et al. Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities. Neural Plast. 2020;2020:1969482.","journal-title":"Neural Plast"},{"issue":"12","key":"1193_CR49","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.3390\/ijms19123782","volume":"19","author":"K Ravina","year":"2018","unstructured":"Ravina K, et al. Intracerebral Delivery of Brain-Derived Neurotrophic Factor Using HyStem((R))-C Hydrogel Implants Improves Functional Recovery and Reduces Neuroinflammation in a Rat Model of Ischemic Stroke. Int J Mol Sci. 2018;19(12):3782.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1193_CR50","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1161\/STROKEAHA.108.531806","volume":"40","author":"M Ploughman","year":"2009","unstructured":"Ploughman M, et al. Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke. 2009;40(4):1490\u20135.","journal-title":"Stroke"},{"issue":"1\u20132","key":"1193_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10495-018-1495-2","volume":"24","author":"X Zhao","year":"2019","unstructured":"Zhao X, et al. Sigma-1 receptor protects against endoplasmic reticulum stress-mediated apoptosis in mice with cerebral ischemia\/reperfusion injury. Apoptosis. 2019;24(1\u20132):157\u201367.","journal-title":"Apoptosis"},{"issue":"10","key":"1193_CR52","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/jnr.24270","volume":"96","author":"R Morihara","year":"2018","unstructured":"Morihara R, et al. Protective effect of a novel sigma-1 receptor agonist is associated with reduced endoplasmic reticulum stress in stroke male mice. J Neurosci Res. 2018;96(10):1707\u201316.","journal-title":"J Neurosci Res"},{"issue":"7","key":"1193_CR53","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3390\/cells11071205","volume":"11","author":"H Kanno","year":"2022","unstructured":"Kanno H, et al. Chaperone-Mediated Autophagy in Neurodegenerative Diseases and Acute Neurological Insults in the Central Nervous System. Cells. 2022;11(7):1205.","journal-title":"Cells"},{"issue":"2","key":"1193_CR54","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s12975-019-00711-0","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, et al. Activation of Sigma-1 Receptor Enhanced Pericyte Survival via the Interplay Between Apoptosis and Autophagy: Implications for Blood-Brain Barrier Integrity in Stroke. Transl Stroke Res. 2020;11(2):267\u201387.","journal-title":"Transl Stroke Res"},{"key":"1193_CR55","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1248\/yakushi1947.82.9_1314","volume":"82","author":"H Ozawa","year":"1962","unstructured":"Ozawa H, Fukuda H, Otsuki I, Chiba S. Antitussive activity and acute toxicity of 2-(2-diethylamino-ethoxy)ethyl alpha, alpha-diethylphenylacetate (oxeladin). Yakugaku Zasshi. 1962;82:1314\u20137.","journal-title":"Yakugaku Zasshi"},{"key":"1193_CR56","doi-asserted-by":"crossref","unstructured":"Talbot J, Waller P. Sephens\u2019 Detection of New Adverse Drug Reactions. 6 ed. 2004: John Wiley and Sons, Ltd.","DOI":"10.1002\/0470014199"},{"key":"1193_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.01.016","volume":"159","author":"L Nguyen","year":"2016","unstructured":"Nguyen L, et al. Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1\u201322.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1193_CR58","doi-asserted-by":"publisher","first-page":"10145","DOI":"10.1038\/s41598-021-89238-9","volume":"11","author":"SJ Lee","year":"2021","unstructured":"Lee SJ, Yeom SY, Lee JY, Park C. Application of the antitussive agents oxelaidin and butamirate as anti-glioma agents. Sci Rep. 2021;11(1):10145.","journal-title":"Sci Rep"}],"container-title":["Translational Stroke Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-023-01193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12975-023-01193-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12975-023-01193-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:16:23Z","timestamp":1730297783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12975-023-01193-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1007\/s12975-023-01193-x","relation":{},"ISSN":["1868-4483","1868-601X"],"issn-type":[{"value":"1868-4483","type":"print"},{"value":"1868-601X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"27 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were approved by the UNTHSC Institutional Animal Care and Use Committee in accordance with the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Derek A. Schreihofer wishes to declare on behalf of himself and John A. Schetz (deceased).U.S. Provisional Patent Application.Title: Drug Repurposing For Delayed Treatment of Ischemic Stroke.Serial NO.: 63\/308,259.Filing data: February 9, 2022.Inventors: D. Schreihofer and J. Schetz.HSC Ref. No.: 2021\u2013016-01.PRO.Attorney File No.: UNTH.P0008US.P1.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}